Contact this trialFirst, we need to learn more about you.
Nivolumab + CCR2/5-inhibitor/Anti-IL-8 for Lung Cancer
Recruiting1 awardPhase 2
New York, New York
This trial is studying nivolumab with or without CCR2/5-inhibitor or anti-IL-8 in treating patients with stage III or stage IV melanoma.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.